EU and US could reach trade deal this weekend - Reuters
Alessandra Cesano, a director at Puma (OTC:PMMAF) Biotechnology (NASDAQ:PBYI), sold 27,000 shares of common stock on July 18, 2025, according to a recent SEC Filing. The shares were sold at a weighted average price of $3.367, resulting in a total transaction value of $90,909. The $172 million market cap company has shown strong financial performance, with InvestingPro data showing a healthy P/E ratio of 4.5 and impressive return on equity of 51%.
The prices for the shares sold ranged from $3.34 to $3.41. Following the transaction, Cesano directly owns 41,850 shares of Puma Biotechnology. The company maintains a "GREAT" financial health score according to InvestingPro analysis, with the stock showing strong returns over the past three months.
The sale was executed under a pre-arranged 10b5-1(c) trading plan adopted on March 11, 2025. Investors should note that the company is scheduled to report its next earnings on July 31, 2025. For comprehensive insider trading analysis and additional insights, access the full Pro Research Report available on InvestingPro.
In other recent news, Puma Biotechnology announced its first-quarter 2025 financial results, which did not meet analysts’ expectations. The company reported earnings per share of $0.06, falling short of forecasts, and generated $46 million in revenue, below the anticipated $47.5 million. Additionally, Puma Biotechnology disclosed the immediate departure of Jeff J. Ludwig from his role as Chief Commercial Officer. The company has not named a replacement for Ludwig, and his departure was officially filed with the Securities and Exchange Commission. These developments come amid Puma Biotechnology’s ongoing efforts to navigate its current business challenges. The company has yet to provide further details on its plans following the executive change. Investors and analysts will likely keep a close watch on how these changes impact the company’s strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.